DOCSLIB.ORG

ATC Klasifikators Ar Superscript Fontiem.Xls

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Kods Nosaukums A Gastrointestinālais trakts un vielmaiņa A01 Līdzekļi mutes dobuma un zobu slimību ārstēšanai A01A Līdzekļi mutes dobuma un zobu slimību ārstēšanai A01AA Līdzekļi kariesa profilaksei A01AA01 Natrii fluoridum A01AA02 Sodium monofluorophosphate A01AA03 Olaflur A01AA04 Stannous fluoride A01AA30 Combinations A01AA51 Sodium fluoride, combinations A01AB Pretinfekcijas un antiseptiskie līdzekļi mutes dobuma slimību vietējai ārstēšanai A01AB02 Hydrogen peroxide A01AB03 Chlorhexidinum A01AB04 Amphotericin b A01AB05 Polynoxylin A01AB06 Domiphen A01AB07 Oxyquinoline A01AB08 Neomycinum A01AB09 Miconazolum A01AB10 Natamycin A01AB11 Dažādi A01AB12 Hexetidinum A01AB13 Tetracycline A01AB14 Benzoxonium chloride A01AB15 Tibezonium iodide A01AB16 Mepartricin A01AB17 Metronidazolum A01AB18 Clotrimazolum A01AB19 Sodium perborate A01AB21 Chlortetracycline A01AB22 Doxycycline A01AB23 Minocycline A01AC Corticosteroids for local oral treatment A01AC01 Triamcinolone A01AC02 Dexamethasone A01AC03 Hydrocortisone A01AC54 Prednisolone, combinations A01AD Citi līdzekļi mutes dobuma slimību vietējai ārstēšanai A01AD01 Epinephrine A01AD02 Benzydamine A01AD05 Acetylsalicylic acid A01AD06 Adrenalone A01AD07 Amlexanox A01AD08 Becaplermin A01AD11 Dažādi A02 Zāles skābes izdales radītu traucējumu ārstēšanai A02A Antacīdi līdzekļi A02AA Magnija savienojumi A02AA01 Magnesium carbonate A02AA02 Magnesium oxide A02AA03 Magnesium peroxide A02AA04 Magnesium hydroxide A02AA05 Magnesium silicate A02AA10 Kombinācijas A02AB Alumīnija savienojumi A02AB01 Aluminium hydroxide A02AB02 Algeldrate A02AB03 Aluminium phosphate A02AB04 Dihydroxialumini sodium carbonate A02AB05 Aluminium acetoacetate A02AB06 Aloglutamol A02AB07 Aluminium glycinate A02AB10 Kombinācijas A02AC Kalcija savienojumi A02AC01 Calcium carbonate A02AC02 Calcium silicate 1/ 88 Kods Nosaukums A02AC10 Kombinācijas A02AD Alumīnija, kalcija un magnija savienojumu kombinācijas un kompleksi A02AD01 Ordinary salt combinations A02AD02 Magaldrate A02AD03 Almagate A02AD04 Hydrotalcitum A02AD05 Almasilate A02AF Antacīdi kombinācijā ar pretmeteorisma līdzekļiem A02AF01 Magaldrate and antiflatulents A02AF02 Vienkāršu sāļu kombinācija un pretmeteorisma līdzekļi A02AG Antacids with antispasmodics A02AH Antacids with sodium bicarbonate A02AX Citas antacīdu līdzekļu kombinācijas A02B Pretčūlas un gastroezofageālā refluksa slimības ārstēšanas līdzekļi A02BA H2 receptoru antagonisti A02BA01 Cimetidinum A02BA02 Ranitidinum A02BA03 Famotidinum A02BA04 Nizatidine A02BA05 Niperotidine A02BA06 Roxatidine A02BA07 Ranitidine bismuth citrate A02BA08 Lafutidine A02BA51 Cimetidine, combinations A02BA53 Famotidine, combinations A02BB Prostaglandins A02BB01 Misoprostol A02BB02 Enprostil A02BC Protonu sūkņa inhibitori A02BC01 Omeprazolum A02BC02 Pantoprazolum A02BC03 Lansoprazolum A02BC04 Rabeprazolum A02BC05 Esomeprazolum A02BC06 dekslansoprazols A02BD Kombinācijas Helicobacter pylori izskaušanai A02BD01 Omeprazole, amoxicillin and metronidazole A02BD02 Lansoprazole, tetracycline and metronidazole A02BD03 Lansoprazole, amoxicillin and metronidazole A02BD04 Pantoprazole, amoxicillin and clarithromycin A02BD05 Omeprazole, amoxicillin and clarithromycin A02BD06 Esomeprazole, amoxicillin and clarithromycin A02BD07 lansoprazole, amoxicillin and clarithromycin A02BD08 bismuth subcitrate, tetracycline and metronidazole A02BX Citi pretčūlas un gastroezofageālā refluksa slimības ārstēšanas līdzekļi A02BX01 Carbenoxolone A02BX02 Sucralfatum A02BX03 Pirenzepine A02BX04 Methiosulfonium chloride A02BX05 Bismuthi subcitras A02BX06 Proglumide A02BX07 Gefarnate A02BX08 Sulglicotide A02BX09 Acetoxolone A02BX10 Zolimidine A02BX11 Troxipide A02BX12 Bismuth subnitrate A02BX13 Alginic acid A02BX51 Carbenoxolone, combinations excl. psycholeptics A02BX71 Carbenoxolone, combinations with psycholeptics A02BX77 Gefarnate, combinations with psycholeptics A02X Other drugs for acid related disorders A03 Zāles funkcionālu gastrointestinālu traucējumu ārstēšanai A03A Zāles funkcionālu kuņģa-zarnu trakta darbības traucējumu ārstēšanai A03AA Sintētiski antiholīnerģiski līdzekļi, esteri ar trešējo aminogrupu A03AA01 Oxyphencyclimine 2/ 88 Kods Nosaukums A03AA03 Camylofin A03AA04 Mebeverinum A03AA05 Trimebutine A03AA06 Rociverine A03AA07 Dicikloverīns A03AA08 Dihexyverine A03AA09 Difemerine A03AA30 Piperidolate A03AB Sintētiski antiholīnerģiski līdzekļi, četraizvietotie amonija sāļi A03AB01 Benzilone A03AB02 Glycopyrronium A03AB03 Oxyphenonium A03AB04 Penthienate A03AB05 Propantheline A03AB06 Otilonii bromidum A03AB07 Methantheline A03AB08 Tridihexethyl A03AB09 Isopropamide A03AB10 Hexocyclium A03AB11 Poldine A03AB12 Mepenzolate A03AB13 Bevonium A03AB14 Pipenzolate A03AB15 Diphemanil A03AB16 (2-benzhydryloxyethyl) diethyl-methylammonium iodide A03AB17 Tiemonium iodide A03AB18 Prifinium bromide A03AB19 Timepidium bromide A03AB21 Fenpiverinium A03AB53 Oxyphenonium, combinations A03AC Synthetic antispasmodics, amides with tertiary amines A03AC02 Dimethylaminopropionylphenothiazine A03AC04 Nicofetamide A03AC05 Tiropramide A03AD Papaverīns, tā atvasinājumi A03AD01 Papaverinum A03AD02 Drotaverinum A03AD30 Moxaverine A03AE Serotonīna receptoru antagonisti A03AE01 Alosetrons A03AE03 Cilansetrons A03AX Citas zāles funkcionālu kuņģa-zarnu trakta traucējumu ārstēšanai A03AX01 Fenpiprāns A03AX02 Diizopromīns A03AX03 Hlorbenzoksamīns A03AX04 Pinaverijs A03AX05 Fenoverīns A03AX06 Idanpramīns A03AX07 Proksazols A03AX08 Alverīns A03AX09 Trepibutons A03AX10 Izometeptēns A03AX11 Karoverīns A03AX12 Floroglucinols A03AX13 Silikoni A03AX30 Trimetildifenilpropilamīns A03AX58 Alverīns, kombinācijas A03B Vilkogas alkaloīdu un to atvasinājumu monopreparāti A03BA Vilkogas alkaloīdi, trešējie amīni A03BA01 Atropinum A03BA03 Hyoscyamine A03BA04 Vilkogas alkaloīdu kopsumma A03BB Pussintētiski vilkogas alkaloīdi, četraizvietotie amonija sāļi A03BB01 Butylscopolaminum A03BB02 Methylatropine A03BB03 Methylscopolamine 3/ 88 Kods Nosaukums A03BB04 Fentonium A03BB05 Cimetropium bromide A03C Antispasmodics in combination with psycholeptics A03CA Synthetic anticholinergic agents in combination with psycholeptics A03CA01 Isopropamide and psycholeptics A03CA02 Clidinium and psycholeptics A03CA03 Oxyphencyclimine and psycholeptics A03CA04 Otilonium bromide and psycholeptics A03CA05 Glycopyrronium and psycholeptics A03CA06 Bevonium and psycholeptics A03CA07 Ambutonium and psycholeptics A03CA08 Diphemanil and psycholeptics A03CA30 Emepronium and psycholeptics A03CA34 Propantheline and psycholeptics A03CB Belladonna and derivatives in combination with psycholeptics A03CB01 Methylscopolamine and psycholeptics A03CB02 Belladonna total alkaloids and psycholeptics A03CB03 Atropine and psycholeptics A03CB04 Methylhomatropine and psycholeptics A03CB31 Hyoscyamine and psycholeptics A03CC Other antispasmodics in combination with psycholeptics A03D Spazmolītisku un pretsāpju līdzekļu kombinācijas A03DA Synthetic anticholinergic agents in combination with analgesics A03DA01 Tropenzilone and analgesics A03DA02 Pitofenone and analgesics A03DA03 Bevonium and analgesics A03DA04 Ciclonium and analgesics A03DA05 Camylofin and analgesics A03DA06 Trospium and analgesics A03DA07 Tiemonium iodide and analgesics A03DB Vilkogas alkaloīdu un to atvasinājumu kombinācijas ar pretsāpju līdzekļiem A03DB04 Butylscopolaminum un pretsāpju līdzekļi A03DC Citi spazmolītiski līdzekļi kombinācijā ar pretsāpju līdzekļiem A03E Spazmolītiski un antiholīnerģiski līdzekļi kombinācijā ar citiem līdzekļiem A03EA Antispasmodics, psycholeptics and analgesics in combination A03ED Spazmolītiski līdzekļi kombinācijā ar citiem līdzekļiem A03F Gastrointestinālā trakta motoriku veicinoši līdzekļi A03FA Prokinētiskie līdzekļi A03FA01 Metoclopramidum A03FA02 Cisapride A03FA03 Domperidonum A03FA04 Bromopride A03FA05 Alizapride A03FA06 Clebopride A04 Līdzekļi pret vemšanu un sliktu dūšu A04A Līdzekļi pret vemšanu un sliktu dūšu A04AA Serotonīna (5HT3) antagonisti A04AA01 Ondansetronum A04AA02 Granisetronum A04AA03 Tropisetronum A04AA04 Dolasetron A04AA05 Palonosetronum A04AD Citi pretvemšanas līdzekļi A04AD01 Scopolamine A04AD02 Cerium oxalate A04AD04 Chlorobutanolum A04AD05 Metopimazine A04AD10 Dronabinol A04AD11 Nabilone A04AD12 Aprepitantum A04AD13 casopitant A04AD51 Scopolamine, kombinācijas A04AD54 Chlorobutanol, kombinācijas A05 Zāles aknu slimību un žults veidošanās un izdales traucējumu ārstēšanai A05A Zāles žults veidošanās un izdales traucējumu ārstēšanai A05AA Žultsskābes preparāti 4/ 88 Kods Nosaukums A05AA01 Chenodeoxycholic acid A05AA02 Acidum ursodeoxycholicum A05AA03 cholic acid A05AB Preparations for biliary tract therapy A05AB01 Nicotinyl methylamide A05AX Citas zāles žults veidošanās un izdales traucējumu ārstēšanai A05AX01 Piprozolin A05AX02 Hymecromonum A05AX03 Cyclobutyrol A05B Zāles aknu slimību ārstēšanai, lipotropiski līdzekļi A05BA Zāles aknu slimību ārstēšanai A05BA01 Arginine glutamate A05BA03 Silymarinum A05BA04 Citiolone A05BA05 Epomediol A05BA06 Ornithine oxoglurate A05BA07 Tidiacic arginine A05BA08 Glycyrrhizic acid A05C Drugs for bile therapy and lipotropics in combination A06 Zāles pret aizcietējumiem A06A Zāles pret aizcietējumiem A06AA Mīkstinoši līdzekļi A06AA01 Paraffinum liquidum A06AA02 Docusate sodium A06AA51 Liquid paraffin, combinations A06AB Zarnu gļotādu kairinoši līdzekļi A06AB01 Oxyphenisatine A06AB02 Bisacodylum A06AB03 Dantron A06AB04 Phenolphthalein A06AB05 Ricini oleum A06AB06 Sennas glikozīdi A06AB07 Amerikas krūklis A06AB08 Natrii picosulfas A06AB09 Bisoxatin A06AB20 Contact laxatives in combination
Recommended publications
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma: a Single-Centre, Observer-Blinded, Randomized Controlled Trial (Trace)

    Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma: a Single-Centre, Observer-Blinded, Randomized Controlled Trial (Trace)

    TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) by Adriana Micheline Workewych A thesis submitted in conformity with the requirements for the degree of Master of Science Institute of Medical Science University of Toronto © Copyright by Adriana Micheline Workewych 2018 TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) Adriana Micheline Workewych Master of Science Institute of Medical Science University of Toronto 2018 ABSTRACT Chronic subdural hematoma (CSDH) is a frequent consequence of head trauma, particularly in older individuals. Given the aging of populations globally, its incidence is projected to increase substantially. Hyperfibrinolysis may be central to CSDH enlargement by causing excessive clot degradation and liquefaction, impeding resorption. The only current standard treatment for CSDH is surgery, however, up to 31% of residual hematomas enlarge, requiring reoperation. Tranexamic acid (TXA), an antifibrinolytic medication that prevents excessively rapid clot breakdown, may help prevent CSDH enlargement, potentially eliminating the need for repeat surgery. To evaluate the feasibility of conducting a trial investigating TXA efficacy in residual CSDH, we conducted an observer-blinded, pilot randomized controlled trial (RCT). We showed this trial was feasible and safe, reporting only minor to moderate AEs, and an attrition rate of 4%. The results from this study will inform the conduct of a double-blinded RCT investigating TXA efficacy in post-operative CSDH management. ii ACKNOWLEDGEMENTS First, I would like to thank my supervisor Dr. Michael Cusimano, my mentor for nearly six years. You have always given me more opportunity than I could have ever hoped for – I could not ask for a more dedicated teacher.
  • Effect of Mgo Additive on Volumetric Expansion of Self-Degradable

    Effect of Mgo Additive on Volumetric Expansion of Self-Degradable

    Effect of MgO Additive on Volumetric Expansion ofSelf-degradable Cements Prepared for The U.S. Department of Energy Energy Efficiency and Renewable Energy Geothermal Technologies Program 1000 Independence Avenue SW Washington, D.C. 20585 Prepared hy Toshifumi Sugama, John Warren, and Thomas Butcher Sustainable Energy Technologies Department Brookhaven National Laboratory Upton, NY 11973-5000 Septemher 2011 Notice: This manuscript has been authored by employee of Brookhaven Science Associates, LLC under Contract No. DE-AC02-98CH t0886 with the U.S. Department of Energy. The publisher by accepting the manuscript for publication acknowledges that the United States Government retains a non.exclusjv~ paid-up, irrevocable, world·wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for the United States Government purposes. DISCLAIMER This work was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, nor any of their contractors, subcontractors or their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or any third party’s use or the results of such use of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof or its contractors or subcontractors.
  • WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T

    WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T (51) International Patent Classification: SHENIA, Iaroslav Viktorovych [UA/UA]; Feodosiyskyy A61L 15/44 (2006.01) A61L 26/00 (2006.01) lane, 14-a, kv. 65, Kyiv, 03028 (UA). A61L 15/54 (2006.01) (74) Agent: BRAGARNYK, Oleksandr Mykolayovych; str. (21) International Application Number: Lomonosova, 60/5-43, Kyiv, 03189 (UA). PCT/UA20 16/0000 19 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 15 February 2016 (15.02.2016) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (30) Priority Data: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, a 2015 01285 16 February 2015 (16.02.2015) UA PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, u 2015 01288 16 February 2015 (16.02.2015) UA SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (72) Inventors; and TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
  • COVID-19: Living Through Another Pandemic Essam Eldin A

    COVID-19: Living Through Another Pandemic Essam Eldin A

    pubs.acs.org/journal/aidcbc Viewpoint COVID-19: Living through Another Pandemic Essam Eldin A. Osman, Peter L. Toogood, and Nouri Neamati* Cite This: https://dx.doi.org/10.1021/acsinfecdis.0c00224 Read Online ACCESS Metrics & More Article Recommendations *sı Supporting Information ABSTRACT: Novel beta-coronavirus SARS-CoV-2 is the pathogenic agent responsible for coronavirus disease-2019 (COVID-19), a globally pandemic infectious disease. Due to its high virulence and the absence of immunity among the general population, SARS- CoV-2 has quickly spread to all countries. This pandemic highlights the urgent unmet need to expand and focus our research tools on what are considered “neglected infectious diseases” and to prepare for future inevitable pandemics. This global emergency has generated unprecedented momentum and scientificefforts around the globe unifying scientists from academia, government and the pharmaceutical industry to accelerate the discovery of vaccines and treatments. Herein, we shed light on the virus structure and life cycle and the potential therapeutic targets in SARS-CoV-2 and briefly refer to both active and passive immunization modalities, drug repurposing focused on speed to market, and novel agents against specific viral targets as therapeutic interventions for COVID-19. s first reported in December 2019, a novel coronavirus, rate of seasonal influenza (flu), which is fatal in only ∼0.1% of A severe acute respiratory syndrome coronavirus 2 (SARS- infected patients.6 In contrast to previous coronavirus CoV-2), caused an outbreak of atypical pneumonia in Wuhan, epidemics (Table S1), COVID-19 is indiscriminately wreaking 1 China, that has since spread globally. The disease caused by havoc globally with no apparent end in sight due to its high this new virus has been named coronavirus disease-2019 virulence and the absence of resistance among the general (COVID-19) and on March 11, 2020 was declared a global population.
  • The Conversion of Wollastonite to Caco3 Considering Its Use for CCS Application As Cementitious Material

    The Conversion of Wollastonite to Caco3 Considering Its Use for CCS Application As Cementitious Material

    applied sciences Article The Conversion of Wollastonite to CaCO3 Considering Its Use for CCS Application as Cementitious Material Kristoff Svensson *, Andreas Neumann, Flora Feitosa Menezes, Christof Lempp and Herbert Pöllmann Institute for Geosciences and Geography, Martin-Luther-University of Halle-Wittenberg, Von-Seckendorff-Platz 3, 06120 Halle (Saale), Germany; [email protected] (A.N.); fl[email protected] (F.F.M.); [email protected] (C.L.); [email protected] (H.P.) * Correspondence: [email protected]; Tel.: +49-345-55-26138 Received: 21 December 2017; Accepted: 8 February 2018; Published: 20 February 2018 Featured Application: Building materials and CCS. Abstract: The reaction of wollastonite (CaSiO3) with CO2 in the presence of aqueous solutions (H2O) and varied temperature conditions (296 K, 323 K, and 333 K) was investigated. The educts (CaSiO3) and the products (CaCO3 and SiO2) were analyzed by scanning electron microscopy (SEM), powder X-ray diffraction (PXRD), and differential scanning calorimetry with thermogravimetry coupled with a mass spectrometer and infrared spectrometer (DSC-TG/MS/IR). The reaction rate increased significantly at higher temperatures and seemed less dependent on applied pressure. It could be shown that under the defined conditions wollastonite can be applied as a cementitious material for sealing wells considering CCS applications, because after 24 h the degree of conversion from CaSiO3 to CaCO3 at 333 K was very high (>90%). As anticipated, the most likely application of wollastonite as a cementitious material in CCS would be for sealing the well after injection of CO2 in the reservoir.
  • Covid-19 Drug Repurposing: Evaluation of Inhibitors in SARS-Cov-2 Infected Cell Lines Clifford Fong

    Covid-19 Drug Repurposing: Evaluation of Inhibitors in SARS-Cov-2 Infected Cell Lines Clifford Fong

    Covid-19 drug repurposing: evaluation of inhibitors in SARS-CoV-2 infected cell lines Clifford Fong To cite this version: Clifford Fong. Covid-19 drug repurposing: evaluation of inhibitors in SARS-CoV-2 infected celllines. [Research Report] Eigenenergy Adelaide South Australia Australia. 2021. hal-03221289 HAL Id: hal-03221289 https://hal.archives-ouvertes.fr/hal-03221289 Submitted on 8 May 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Covid-19 drug repurposing: evaluation of inhibitors in SARS-CoV-2 infected cell lines Clifford W. Fong Eigenenergy, Adelaide, South Australia, Australia. Email: [email protected] Keywords: Caco-2, VeroE6, VeroCCL81, HuH, Calu-3, COVID-2019, SARS-CoV-2; ACE2 receptor binding, spike serine proteases, S-RBD, TMPRSS2, IC50, linear free energy relationships, HOMO-LUMO, quantum mechanics; Abbreviations: Structure activity relationships SAR, ΔGdesolv,CDS free energy of water desolvation, ΔGlipo,CDS lipophilicity free energy, cavity dispersion solvent structure of the first solvation shell CDS, Dipole moment DM, Molecular Volume Vol, HOMO highest occupied molecular orbital, LUMO lowest unoccupied molecular orbital, HOMO-LUMO energy gap, linear free energy relationships LFER, Receptor binding domain of S protein of SARS-CoV-2 S- RBD, transmembrane serine 2 protease TMPRSS2, angiotensin-converting enzyme 2 ACE2.
  • Camostat Mesylate May Reduce Severity of Coronavirus Disease

    Camostat Mesylate May Reduce Severity of Coronavirus Disease

    Critical Care Brief Report Explorations Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation 11/27/2020 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= by https://journals.lww.com/ccejournal from Downloaded Heike Hofmann-Winkler, PhD1; Onnen Moerer , MD2; Sabine Alt-Epping, MD2; 2 2 2 2 Downloaded Anselm Bräuer, MD ; Benedikt Büttner, MD ; Martin Müller, MD ; Torben Fricke ; Julian Grundmann2; Lars-Olav Harnisch, MD2; Daniel Heise, MD2; Andrea Kernchen2; from 2 3 4 1 https://journals.lww.com/ccejournal Meike Pressler, MD ; Caspar Stephani, MD ; Björn Tampe, MD ; Artur Kaul, PhD ; Sabine Gärtner1; Stefanie Kramer1; Stefan Pöhlmann, PhD1,5; Martin Sebastian Winkler, MD2 Objectives: Severe acute respiratory syndrome coronavirus 2 cell Assessment score decreased in the camostat group but remained by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= entry depends on angiotensin-converting enzyme 2 and transmem- elevated in the hydroxychloroquine group. The decline in disease brane serine protease 2 and is blocked in cell culture by camostat severity in camostat mesylate treated patients was paralleled by a mesylate, a clinically proven protease inhibitor. Whether camostat decline in inflammatory markers and improvement of oxygenation. mesylate is able to lower disease burden in coronavirus disease Conclusions: The severity of coronavirus disease 2019 decreased 2019 sepsis is currently unknown. upon camostat mesylate treatment within a period of 8 days and a Design: Retrospective observational case series. similar effect was not observed in patients receiving hydroxychloro- Setting: Patient treated in ICU of University hospital Göttingen, quine. Camostat mesylate thus warrants further evaluation within ran- Germany. domized clinical trials. Patients: Eleven critical ill coronavirus disease 2019 patients with Key Words: camostat mesylate; coronavirus disease 2019; sepsis; organ failure were treated in ICU.
  • Prohibited Substances List

    Prohibited Substances List

    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).